Corvus Pharmaceuticals (NASDAQ:CRVS – Get Free Report) and AbCellera Biologics (NASDAQ:ABCL – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, analyst recommendations, dividends, valuation, earnings and profitability.
Institutional & Insider Ownership
46.6% of Corvus Pharmaceuticals shares are held by institutional investors. Comparatively, 61.4% of AbCellera Biologics shares are held by institutional investors. 28.5% of Corvus Pharmaceuticals shares are held by company insiders. Comparatively, 28.9% of AbCellera Biologics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Risk & Volatility
Corvus Pharmaceuticals has a beta of 0.7, meaning that its stock price is 30% less volatile than the S&P 500. Comparatively, AbCellera Biologics has a beta of 0.73, meaning that its stock price is 27% less volatile than the S&P 500.
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Corvus Pharmaceuticals | 1 | 0 | 5 | 0 | 2.67 |
| AbCellera Biologics | 1 | 3 | 3 | 0 | 2.29 |
Corvus Pharmaceuticals currently has a consensus price target of $14.25, indicating a potential upside of 109.87%. AbCellera Biologics has a consensus price target of $7.75, indicating a potential upside of 77.35%. Given Corvus Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts clearly believe Corvus Pharmaceuticals is more favorable than AbCellera Biologics.
Profitability
This table compares Corvus Pharmaceuticals and AbCellera Biologics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Corvus Pharmaceuticals | N/A | -26.11% | -20.48% |
| AbCellera Biologics | -493.42% | -17.21% | -12.76% |
Earnings and Valuation
This table compares Corvus Pharmaceuticals and AbCellera Biologics”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Corvus Pharmaceuticals | N/A | N/A | -$62.29 million | ($0.53) | -12.81 |
| AbCellera Biologics | $28.83 million | 45.37 | -$162.86 million | ($0.57) | -7.67 |
Corvus Pharmaceuticals has higher earnings, but lower revenue than AbCellera Biologics. Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than AbCellera Biologics, indicating that it is currently the more affordable of the two stocks.
Summary
AbCellera Biologics beats Corvus Pharmaceuticals on 7 of the 13 factors compared between the two stocks.
About Corvus Pharmaceuticals
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.
About AbCellera Biologics
AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company’s preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.
Receive News & Ratings for Corvus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corvus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
